S&P 500   5,134.98 (-0.04%)
DOW   39,009.32 (-0.20%)
QQQ   445.00 (-0.14%)
AAPL   174.91 (-2.64%)
MSFT   415.58 (+0.02%)
META   503.39 (+0.22%)
GOOGL   132.48 (-3.40%)
AMZN   178.95 (+0.41%)
TSLA   190.43 (-6.03%)
NVDA   851.72 (+3.52%)
NIO   5.40 (-6.57%)
AMD   207.90 (+2.60%)
BABA   72.04 (-3.46%)
T   16.88 (-0.59%)
F   12.97 (+4.18%)
MU   96.71 (+1.64%)
CGC   3.02 (-5.92%)
GE   159.58 (+0.59%)
DIS   112.80 (+0.76%)
AMC   4.29 (-1.61%)
PFE   25.88 (-2.67%)
PYPL   59.41 (-1.87%)
XOM   104.56 (-1.21%)
S&P 500   5,134.98 (-0.04%)
DOW   39,009.32 (-0.20%)
QQQ   445.00 (-0.14%)
AAPL   174.91 (-2.64%)
MSFT   415.58 (+0.02%)
META   503.39 (+0.22%)
GOOGL   132.48 (-3.40%)
AMZN   178.95 (+0.41%)
TSLA   190.43 (-6.03%)
NVDA   851.72 (+3.52%)
NIO   5.40 (-6.57%)
AMD   207.90 (+2.60%)
BABA   72.04 (-3.46%)
T   16.88 (-0.59%)
F   12.97 (+4.18%)
MU   96.71 (+1.64%)
CGC   3.02 (-5.92%)
GE   159.58 (+0.59%)
DIS   112.80 (+0.76%)
AMC   4.29 (-1.61%)
PFE   25.88 (-2.67%)
PYPL   59.41 (-1.87%)
XOM   104.56 (-1.21%)
S&P 500   5,134.98 (-0.04%)
DOW   39,009.32 (-0.20%)
QQQ   445.00 (-0.14%)
AAPL   174.91 (-2.64%)
MSFT   415.58 (+0.02%)
META   503.39 (+0.22%)
GOOGL   132.48 (-3.40%)
AMZN   178.95 (+0.41%)
TSLA   190.43 (-6.03%)
NVDA   851.72 (+3.52%)
NIO   5.40 (-6.57%)
AMD   207.90 (+2.60%)
BABA   72.04 (-3.46%)
T   16.88 (-0.59%)
F   12.97 (+4.18%)
MU   96.71 (+1.64%)
CGC   3.02 (-5.92%)
GE   159.58 (+0.59%)
DIS   112.80 (+0.76%)
AMC   4.29 (-1.61%)
PFE   25.88 (-2.67%)
PYPL   59.41 (-1.87%)
XOM   104.56 (-1.21%)
S&P 500   5,134.98 (-0.04%)
DOW   39,009.32 (-0.20%)
QQQ   445.00 (-0.14%)
AAPL   174.91 (-2.64%)
MSFT   415.58 (+0.02%)
META   503.39 (+0.22%)
GOOGL   132.48 (-3.40%)
AMZN   178.95 (+0.41%)
TSLA   190.43 (-6.03%)
NVDA   851.72 (+3.52%)
NIO   5.40 (-6.57%)
AMD   207.90 (+2.60%)
BABA   72.04 (-3.46%)
T   16.88 (-0.59%)
F   12.97 (+4.18%)
MU   96.71 (+1.64%)
CGC   3.02 (-5.92%)
GE   159.58 (+0.59%)
DIS   112.80 (+0.76%)
AMC   4.29 (-1.61%)
PFE   25.88 (-2.67%)
PYPL   59.41 (-1.87%)
XOM   104.56 (-1.21%)
NASDAQ:MRTX

Mirati Therapeutics (MRTX) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$58.70
$58.70
50-Day Range
$58.70
$59.28
52-Week Range
$27.30
$64.41
Volume
N/A
Average Volume
2.76 million shs
Market Capitalization
$4.12 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$60.00

Mirati Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.21 Rating Score
Upside/​Downside
2.2% Upside
$60.00 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-0.68
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$433,243 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($11.39) to ($9.81) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.29 out of 5 stars

Medical Sector

923rd out of 948 stocks

Pharmaceutical Preparations Industry

429th out of 441 stocks


MRTX stock logo

About Mirati Therapeutics Stock (NASDAQ:MRTX)

Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. In addition, the company pipeline comprises the MRTX1719, an investigational synthetic lethal PRMT5 inhibitor designed to target the PRMT5/methylthioadensoine (MTA) complex and is in clinical development; MRTX0902, a selective SOS1 inhibitor that improves anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors, and is in clinical development; and MRTX1133, an investigational lead KRAS G12D compound. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and Zai Lab Ltd. to research, develop, manufacture, and commercialize adagrasib in various indications. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.


MRTX Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Mirati Therapeutics Inc MRTX
Mirati Therapeutics Gets CHMP Backing for Krazati
See More Headlines
Receive MRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mirati Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/06/2023
Today
3/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:MRTX
Fax
N/A
Employees
587
Year Founded
2013

Price Target and Rating

Average Stock Price Target
$60.00
High Stock Price Target
$82.00
Low Stock Price Target
$37.00
Potential Upside/Downside
+2.2%
Consensus Rating
Hold
Rating Score (0-4)
2.21
Research Coverage
14 Analysts

Profitability

Net Income
$-740,870,000.00
Net Margins
-1,900.65%
Pretax Margin
-1,899.99%

Debt

Sales & Book Value

Annual Sales
$12.44 million
Book Value
$17.31 per share

Miscellaneous

Free Float
67,861,000
Market Cap
$4.12 billion
Optionable
Optionable
Beta
0.77

Social Links

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Dr. Charles M. Baum M.D. (Age 66)
    Ph.D., Founder, President, CEO & Director
    Comp: $1.07M
  • Dr. James G. Christensen Ph.D. (Age 56)
    Executive VP & Chief Scientific Officer
    Comp: $1.76M
  • Dr. Alan Bart Sandler M.D. (Age 67)
    Executive VP & Chief Medical Officer
    Comp: $591k
  • Mr. Aaron Ondrey (Age 48)
    Chief Financial Officer
  • Ms. Betsy Gelfand CPA
    Chief Accounting Officer, Principal Accounting Officer & VP of Finance
  • Mr. John B. Moriarty Jr. (Age 56)
    J.D., Chief Legal Officer & Corporate Secretary
  • Mr. Peter Lee
    Chief Compliance Officer
  • Mr. Michael E. Paolucci (Age 64)
    Chief People Officer
  • Mr. Benjamin J. Hickey M.B.A. (Age 49)
    Chief Commercial Officer
    Comp: $769.03k
  • Dr. Kelly Covello Ph.D.
    VP & Head of Medical Affairs














MRTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Mirati Therapeutics stock right now?

14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Mirati Therapeutics in the last year. There are currently 11 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MRTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MRTX, but not buy additional shares or sell existing shares.
View MRTX analyst ratings
or view top-rated stocks.

What is Mirati Therapeutics' stock price target for 2024?

14 equities research analysts have issued 1 year price objectives for Mirati Therapeutics' stock. Their MRTX share price targets range from $37.00 to $82.00. On average, they expect the company's stock price to reach $60.00 in the next twelve months. This suggests a possible upside of 2.2% from the stock's current price.
View analysts price targets for MRTX
or view top-rated stocks among Wall Street analysts.

How were Mirati Therapeutics' earnings last quarter?

Mirati Therapeutics, Inc. (NASDAQ:MRTX) released its quarterly earnings results on Monday, November, 6th. The biotechnology company reported ($2.49) EPS for the quarter, beating analysts' consensus estimates of ($2.83) by $0.34. The biotechnology company earned $16.40 million during the quarter, compared to analysts' expectations of $18.80 million. Mirati Therapeutics had a negative trailing twelve-month return on equity of 82.15% and a negative net margin of 1,900.65%. The company's revenue was up 203.7% on a year-over-year basis. During the same period in the prior year, the company posted ($3.09) earnings per share.

What other stocks do shareholders of Mirati Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mirati Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), AbbVie (ABBV), QUALCOMM (QCOM), BioMarin Pharmaceutical (BMRN), Micron Technology (MU), Netflix (NFLX), Block (SQ), Alibaba Group (BABA) and DocuSign (DOCU).

Who are Mirati Therapeutics' major shareholders?

Mirati Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (7.56%), Avoro Capital Advisors LLC (6.97%), Simplicity Solutions LLC (4.47%), Braslyn Ltd. (4.47%), Alpine Associates Management Inc. (2.68%) and Hsbc Holdings PLC (1.12%). Insiders that own company stock include Benjamin Hickey, Boxer Capital, Llc, Bruce L A Carter, Charles M Baum, David D Meek, Faheem Hasnain, Jamie Christensen, Julie M Cherrington, Julie M Cherrington, Laurie Stelzer, Ltd Braslyn and Vickie S Reed.
View institutional ownership trends
.

Does Mirati Therapeutics have any subsidiaries?
The following companies are subsidiares of Mirati Therapeutics: MethylGene, MethylGene Inc., and Mirati Therapeutics B.V..
Read More
This page (NASDAQ:MRTX) was last updated on 3/4/2024 by MarketBeat.com Staff